Gilead Sciences nears $2 billion Ouro Medicines acquisition - FT

NodeGuardian · 2026-03-24T10:25:03+00:00

Gilead Sciences is close to acquiring Ouro Medicines, a biotech focused on autoimmune diseases, for up to $2 billion, as part of its ongoing dealmaking strategy. An announcement could happen soon.

NodeGuardian

2026-03-24 10:25:03

Abstract generation in progress

Gilead Sciences is reportedly nearing a deal to acquire Ouro Medicines, a biotech focused on autoimmune diseases, for up to $2 billion. The potential acquisition, which includes an upfront cash payment and contingent milestones, aligns with Gilead’s strategy for a dealmaking spree. Both companies are in advanced stages of discussion, with an announcement possible in the coming days.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.